23andMe Target of Unusually High Options Trading (NASDAQ:ME)

23andMe Holding Co. (NASDAQ:ME) saw some unusual options trading activity on Tuesday. Stock investors acquired 2,416 put options on the company. This represents an increase of approximately 139% compared to the typical daily volume of 1,009 put options.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 23andMe in a research note on Saturday, March 22nd.

Institutional Trading of 23andMe

Several hedge funds have recently bought and sold shares of ME. Shay Capital LLC boosted its position in shares of 23andMe by 71.7% in the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock worth $2,283,000 after purchasing an additional 293,358 shares during the period. FMR LLC lifted its stake in shares of 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after buying an additional 192,099 shares in the last quarter. Geode Capital Management LLC boosted its holdings in 23andMe by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after buying an additional 28,252 shares during the period. Virtu Financial LLC purchased a new stake in 23andMe in the 4th quarter worth $49,000. Finally, MassMutual Private Wealth & Trust FSB bought a new stake in 23andMe during the fourth quarter valued at about $40,000. Institutional investors own 36.10% of the company’s stock.

23andMe Stock Down 18.4 %

Shares of NASDAQ:ME opened at $0.53 on Thursday. The firm’s 50 day moving average price is $2.38 and its 200-day moving average price is $3.83. The stock has a market capitalization of $14.23 million, a PE ratio of -0.03 and a beta of 1.19. 23andMe has a twelve month low of $0.53 and a twelve month high of $12.76.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative return on equity of 170.07% and a negative net margin of 183.39%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.